Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2013-08-08 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
2013年第三次临时股东大会资料
AGM Information Classification · 95% confidence The document is titled as materials for the 2013 third extraordinary general meeting of shareholders of Kunming Pharmaceutical Group Co., Ltd. It includes detailed agenda items, voting procedures, and multiple proposals to be voted on, such as the fund-raising management system, a patent licensing agreement, and the use of idle raised funds for cash management. The content is focused on the meeting materials and agenda for a shareholders' meeting rather than the results of voting or the meeting minutes. It is not a full annual or interim report, nor an earnings release or audit report. The document is comprehensive and over 13,000 characters, indicating it is the actual meeting materials, not just an announcement. Therefore, it fits the category of AGM Information (AGM-R).
2013-08-08 Chinese
2013年第二次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the procedures and legality of a company's 2013 second extraordinary general meeting (临时股东大会). It details the notice, attendance, voting procedures, and resolutions passed at the meeting. It does not contain financial statements or results, nor is it a report or announcement of financial performance. It is not a proxy solicitation or voting results announcement but a legal opinion on the meeting's compliance with laws and company bylaws. Therefore, it fits best under Legal Proceedings Report (LTR) as it relates to legal compliance and opinions on corporate governance matters.
2013-08-06 Chinese
2013年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2013 second extraordinary general meeting of shareholders of Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results on various proposals including director resignation and appointment, establishment of a new plant, and amendments to the company bylaws. It also includes a legal opinion confirming the validity of the meeting and voting procedures. The document is not a full report but an official announcement of voting results from a shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2013-08-06 Chinese
独立董事关于以募集资金置换先期投入募投项目的自筹资金的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion from the independent directors regarding the use of raised funds to replace previously invested self-raised funds in a project. It references regulatory guidelines on the management and use of raised funds by listed companies, and confirms compliance with relevant laws and approvals. The content focuses on capital management and financing activities related to the company's fundraising and use of proceeds. The document length is short (666 characters), but it contains substantive content about the use of capital raised through a public offering. Therefore, it is best classified as a Capital/Financing Update (CAP).
2013-08-05 Chinese
关于签署募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement related to the management and use of raised funds from a share issuance. It details the opening of special accounts for the raised funds, the roles of the sponsoring institution, and the regulatory compliance measures. The document does not contain financial statements or detailed financial performance data but focuses on the management and supervision of capital raised. This fits the category of Capital/Financing Update (CAP), as it relates to fundraising activities and capital management.
2013-08-05 Chinese
使用部分闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (招商证券股份有限公司) regarding the use of idle raised funds by 昆明制药集团股份有限公司 for cash management. It references regulatory guidelines on the management and use of raised funds, details the amount raised, the investment plan, risk control measures, and the sponsoring institution's opinion approving the use of idle funds for low-risk cash management products. The document is not an annual or interim financial report, nor an earnings release or management discussion. It is a regulatory compliance and verification report related to fundraising and fund usage, typical of an Audit Report / Information (AR) type filing, as it involves due diligence, verification, and audit-related opinions on the use of funds. The document length is 2212 characters, which is consistent with a standalone audit or verification report rather than a full annual or interim report. Therefore, the best classification is AR (Audit Report / Information). FY 2013
2013-08-05 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.